7th Annual Live Medical Crossfire®: Hematologic Malignancies
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Addressing Clinical Gaps in Thyroid Cancer Management: Taking Action with Precision Methods to Personalize Treatment Decision-Making
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
Evolving Evidence in Pediatric Brain Cancer: Spotlight on MAPK Inhibitors
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
Pembrolizumab Plus Chemo Does Not Significantly Improve Survival in TKI-resistant, EGFR+ NSCLC
The addition of pembrolizumab to pemetrexed and platinum-based chemotherapy resulted in a numerical, but not statistically significant, improvement in progression-free survival or overall survival vs chemotherapy plus placebo in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer.
Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOCJune 6th 2023
Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.
Post-hoc Analysis Shows Maintenance Niraparib Provides Additional Antitumor Activity in Advanced Ovarian CancerJune 6th 2023
The use of maintenance niraparib enhanced antitumor activity and led to a clinically meaningful increase in progression-free survival vs placebo for patients with newly diagnosed advanced ovarian cancer who displayed measurable residual disease after first-line platinum-based chemotherapy, according to findings from a post hoc subgroup analysis of the phase 3 PRIME study.
FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial CancerJune 6th 2023
The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.
Extended Lymphadenectomy Does Not Lead to Survival Benefit in MIBCJune 6th 2023
Extended lymphadenectomy at the time of radical cystectomy did not produce a significant improvement in disease-free survival (DFS) or overall survival (OS) vs standard lymphadenectomy for patients with muscle-invasive bladder cancer.
Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced MelanomaJune 6th 2023
The LAG-3 inhibitor fianlimab plus cemiplimab produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study.
ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCLJune 6th 2023
Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.
Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal CarcinomaJune 6th 2023
The addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurrence compared with chemoradiotherapy alone as frontline therapy in patients with locally advanced nasopharyngeal carcinoma, according to findings from the phase 3 CONTINUUM trial.
Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast CancerJune 6th 2023
Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
Long-Term KEYNOTE-426 Data Continue to Support Frontline Pembrolizumab Plus Axitinib as SOC for Advanced ccRCCJune 5th 2023
The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.
Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC
The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.
ABBV-011 Showcases Early Tolerability, Antitumor Activity in Small Cell Lung CancerJune 5th 2023
The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.
Cilta-cel Possesses Potential to Be New SOC for Lenalidomide-refractory Myeloma After First Relapse
Ciltacabtagene autoleucel significantly improved progression-free survival over standard-of-care pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
Fruquintinib/BSC Demonstrates OS/PFS Benefit in Refractory mCRC, Irrespective of Prior Treatment
Treatment with fruquintinib plus best supportive care led to improved overall survival and progression-free survival vs placebo plus best supportive care in patients with refractory metastatic colorectal cancer, irrespective of number of prior lines of therapy or type of prior treatment.
Lasofoxifene/Abemaciclib Shows Clinically Meaningful Efficacy in ER+/HER2- ESR1-Mutant Breast CancerJune 5th 2023
Longer follow-up data from the phase 2 ELAINE-2 study demonstrated that treatment with lasofoxifene and abemaciclib resulted in clinically meaningful antitumor activity as well as continued tolerability with no new safety signals for patients with estrogen receptor-positive HER2-negative ESR1-mutated breast cancer who previously received CDK4/6 inhibitors.
Doxorubicin/Zalifrelimab/Balstilimab Generates Activity in Soft Tissue SarcomaJune 5th 2023
Treatment with doxorubicin plus zalifrelimab and balstilimab produced a favorable 6-month progression-free survival rate in patients with difficult-to-treat soft tissue sarcoma subtypes unlikely to respond to doxorubicin or immune checkpoint inhibitor monotherapy.
TAS-102 Plus Bevacizumab Fails to Extend OS in Unresectable mCRCJune 5th 2023
The combination of trifluridine/tipiracil and bevacizumab did not demonstrate a significant overall survival benefit vs capecitabine plus bevacizumab in patients with unresectable, metastatic colorectal cancer ineligible for intensive chemotherapy.
Lenvatinib Plus Pembrolizumab Maintains Survival Benefit in Advanced RCCJune 5th 2023
Lenvatinib plus pembrolizumab (Keytruda) showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma.
HER3-DXd Elicits Responses and Safety in Heavily Pretreated ER+ Breast Cancer and TNBCJune 5th 2023
Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.
Enfortumab Vedotin Plus Pembrolizumab Produces Durable Responses, Safety in Metastatic Urothelial CarcinomaJune 5th 2023
The combination of enfortumab vedotin-ejfv and pembrolizumab generated rapid and durable responses and demonstrated a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.
Cabozantinib Plus Nivolumab/Ipilimumab Improves PFS, DCR in Metastatic Soft Tissue SarcomaJune 5th 2023
The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma.
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal MelanomaJune 5th 2023
The protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 demonstrated preliminary antitumor activity and acceptable safety for patients with recurrent high-grade glioma and advanced or metastatic uveal melanoma, according to data from the dose-expansion portion of a phase 1 trial presented at the 2023 ASCO Annual Meeting.